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Melanoma-inhibiting activity/cartilage-derived reti-
noic acid-sensitive protein, a 11 kDa protein, is
mainly expressed in cartilage during embryogenesis,
and is related to invasion, metastasis, and immuno-
modulation of melanoma and glioma cells in vivo
and in vitro. Here, we describe an alternative splice
product of this gene termed melanoma-inhibiting
activity (splice), lacking exon 2 of the original
protein. A predicted frameshift by alternate splicing
results in a unique C-terminal portion of the protein.
Consistent with this, a protein migrating at the pre-
dicted molecular weight of the splice form (3.5 kDa)
was detected using an N-terminal speci®c antibody.
This band was undetectable when using a C-terminal
speci®c antibody. In addition, we describe the
expression pattern of melanoma-inhibiting activity
(splice) in different human tumors. Expression was
shown in tissue samples of ®ve of six primary
melanomas, 11 of 12 primary sites of metastatic
melanomas, 10 of 10 systemic metastases of mela-
nomas, four of four central nervous system metas-
tases of melanomas, six of eight primary melanoma
cultures, and ®ve of ®ve melanoma cell lines. Only a
faint signal was obtained in tissue samples of ®ve of
six naevi. Interestingly, seven of eight nonmelano-
cytic tissue samples and ®ve of seven glioma cell
lines showed weak expression of melanoma-inhibit-
ing activity (splice). Approaching ®rst functional
aspects, reverse transcriptase±polymerase chain reac-
tion showed weak expression of melanoma-inhibit-
ing activity (splice) in relation to melanoma-
inhibiting activity in nonmelanocytic and strong
expression in melanocytic cells. Staining with a spe-
ci®c anti-serum raised against a synthetic peptide
resembling the amino acid sequence of melanoma-
inhibiting activity (splice) showed a more nuclear
staining pattern in comparison with melanoma-
inhibiting activity. Furthermore, incubation of mela-
noma and glioma cell cultures with transforming
growth factor-b2 showed inverse regulation of the
mRNA of melanoma-inhibiting activity and mela-
noma-inhibiting activity (splice), both suggesting
also a different function within the physiologic role
of this unique family of proteins. Melanoma-inhibit-
ing activity (splice) has no homology to any other
known protein so far. Whereas the biologic function
of melanoma-inhibiting activity (splice) is not clear
yet, it might provide a relevant diagnostic and thera-
peutic tool for malignant melanomas. Key words:
alternative splicing/cartilage-derived retinoic acid-sensitive
protein/melanoma-inhibiting activity/melanoma. J Invest
Dermatol 119:562±569, 2002
T
he 11 kDa protein melanoma-inhibiting activity (for
review: Apfel et al, 1998; Bosserhoff et al, 1999a) has
been previously identi®ed within growth-inhibitory
activities secreted by a primary culture from the
central nervous system (CNS) metastasis of a patient
with malignant melanoma and was puri®ed from tissue culture
supernatants (Apfel et al, 1992). Recent studies have shown that the
expression of melanoma-inhibiting activity (MIA) in adult tissue is
mainly restricted to malignant melanoma, cartilage, and to a lesser
degree to breast carcinoma, carcinoma of the colon, and
glioblastoma (Dietz and Sandell, 1996; Bosserhoff et al, 1999a; de
Vries et al, 1999). MIA expression is correlated to some degree with
embryonic development as well as with differentiation of cartilage
cells in vitro (Dietz and Sandell, 1996). Summarizing both biologic
functions, the gene/protein is now referred to as MIA/cartilage-
derived retinoic acid-sensitive protein (MIA/CD-RAP). The
MIA/CD-RAP-gene is located on chromosome 19q13.32±33
(Koehler et al, 1996). Recently, some other proteins with similar
sequences were described, all of which reside in one family of genes
(Cohen-Salmon et al, 2000; Pan et al, 2000; Robertson et al, 2000;
Rendtorff et al, 2001).
Comparing expression levels in melanocytes, melanocytic nevi,
and melanomas, MIA expression was shown to parallel the
progressive malignancy of melanomas (Bosserhoff et al, 1999b). In
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clinical studies, MIA serum levels correlate with the clinical tumor
stage in melanoma patients, providing an enzyme-linked immu-
nosorbent assay (Roche Diagnostics, Mannheim, Germany) to
monitor therapy and progression of this disease. Serum levels are
enhanced in 13% of patients with stage I melanoma and in 100% of
patients with stage IV melanoma as tested by enzyme-linked
immunosorbent assay (Bosserhoff et al, 1999b; Dreau et al, 1999;
Brochez and Naeyaert, 2000).
The biologic function of MIA in adult organisms is still unclear,
but evidence is growing that it might be involved in cellular
motility, metastasis, and modulation of immune responses. These
effects may be explained by interaction with components of the
extracellular matrix, such as laminin and ®bronectin (Bosserhoff et
al, 1997). Therefore, MIA may have a function in regulating
detachment of melanoma and possibly other cells from the
extracellular matrix, which is an important step in metastasis, and
in cartilage development. Furthermore, MIA inhibits proliferation
and activation of peripheral blood mononuclear cells in a
concentration-dependent manner. As cytotoxicity of T cells is
mediated by a4/b1 and a5/b1 integrins, an immune escape of
malignant melanoma and possibly other tumors producing MIA
could be facilitated by this mechanism (Jachimzak et al, in press).
During the process of the characterization of MIA using
northern blot analysis and reverse transcriptase±polymerase chain
reaction (reverse transcriptase±PCR), we detected a second tran-
script, indicating possible alternate splicing. Here, we describe the
characterization, cloning, sequencing, and expression pattern of this
novel 3.5 kDa peptide MIA(splice) as well as its tissue distribution
and ®rst data indicating a different functional role in comparison
with MIA. An alternative splice form could be critically involved in
the biologic function of MIA, could broaden the diagnostic value
of MIA, give insight into the physiologic role of this protein, and
might even be a target for novel therapeutic strategies.
MATERIALS AND METHODS
Primary cultures and cell lines The melanoma cell lines CRL-1424
and HTB-69 were obtained from American type culture collection
(ATCC). The other melanoma cell lines designated with ``HTZ'' were
established from human melanoma central nervous system tumor
metastasis. All melanoma cultures were grown in Ham's F-12/Dulbecco's
modi®ed Eagle's medium supplemented with 10% fetal bovine serum as
monolayers under standard culture conditions as described elsewhere
(Bogdahn et al, 1989). HTZ-19 cells were grown in serum-free medium
(Bogdahn et al, 1989). All glioma cell lines (HTB-10, HTB-11, HTB-
185, HTB-186) that were obtained from ATTC were grown in
Dulbecco's modi®ed Eagle's medium with 10% fetal bovine serum as
standard monolayer cultures. All other glioma cell lines designated
``HTZ'' were established from human tumor biopsies and grown under
the same conditions.
To elucidate the role of transforming growth factor (TGF)-b in the
regulation of MIA, cultures were treated with 10 ng TGF-b2 per ml
(Boehringer Mannheim, Germany), and expression of MIA and
MIA(splice) mRNA was analyzed by northern blot after harvesting cells
after 3, 6, 12, 24, and 48 h in comparison with an untreated control.
Cloning and sequencing of recombinant cDNA clones Total RNA
was prepared according to the method of Chomczynski and Sacchi
(1987)). The RNA was ampli®ed by reverse transcriptase±PCR as
described with speci®c primers speci®ed below and was run on an
agarose gel. A southern blot was performed and stained with a speci®c
32P-labeled 459 bp probe derived from the MIA sequence. Two signals,
one for MIA and a second one, later identi®ed as MIA(splice), were
found. The ®lm was used as a mask to cut out the corresponding second
signal from an identical reverse transcriptase±PCR reaction. The
ampli®ed reverse transcriptase±PCR product was electroeluted and
cloned into the vector pQE40 (Qiagen, GMbH, Max-Vollmer-Strasse 4,
40724 Hilden, Germany) under standard conditions. Clones were
selected and ampli®ed, and plasmids were prepared by alkaline lysis
(Birnboim and Doly, 1979). Sequencing of the plasmids was performed
according to a standard protocol (Sanger et al, 1977).
Reverse transcriptase±PCR The primer pair MIA-forward (5¢-CAT
GCA TGC GGT CCT ATG CCC AAG CTG-3¢) and MIA-reverse
(5¢-GAT AAG CTT TCA CTG GCA GTA GAA ATC-3¢) was em-
ployed for reverse transcriptase±PCR except for the studies shown in
Fig 1 and Table I, there the following primers were used: for
ampli®cation of MIA, a forward primer hybridizing to the exon±exon
boundary of exon 2/3 (5¢-TGG GGA GGC AGC GTT CAG G-3¢),
and for MIA(splice), a forward primer binding to the exon±exon
boundary of exon 1/3 (5¢-GAC CAG GAG TGC AGC CTT CAG-3¢)
were designed. As reverse primers, MIA-reverse (5¢-ACA TCG ACT
TTG CCA GGT TTC AGG-3¢) and MIA(splice)-reverse (5¢-TCA CAT
CGA CTT TGC CAG TTT CA-3¢) were used. The latter primers
result in fragments of 100 bp for MIA and 114 bp for MIA(splice).
Twenty-eight cycles of PCR for MIA or 32 cycles of PCR for
MIA(splice) were done using the following pro®le: 45 s at 95°C, 30 s at
55°C, and 60 s at 72°C. PCR reaction products were separated on a
1.8% agarose gel and subjected to southern blot analysis.
In parallel, b-actin or GAPDH mRNA was ampli®ed to con®rm
equal amounts and integrity of different RNA preparations. The same
reverse transcriptase±PCR conditions were used to perform PCR in all
primary cultures shown here. Results were con®rmed in part by direct
sequencing of reverse transcriptase±PCR products and by northern
blotting.
Northern blots RNA was isolated as described above. Total cellular
RNA (20 mg per lane) was loaded on a 1% formaldehyde-agarose gel
and transferred to nylon membranes according to a standard protocol
(Sambrook et al, 1989). The complete human MIA cDNA insert was
used as a probe for both MIA and MIA(splice) RNA. Final washes were
performed in standard sodium citrate/chloride buffer two times for 1 h
each at 68°C.
Western blots Supernatants from cell cultures for western blots were
prepared with centricon-3 ultra®ltration vials using a kit of Amicon,
Millipore GmbH, Am Kronberger Hang 5, 65824 Schwalbach,
Germany. The samples were separated on a high-resolution tricine-
polyacrylamide gel electrophoresis according to the method described by
SchaÈgger and Jagow (1987). Western transfers to nitrocellulose
membranes were performed according to the method of Khyse-
Anderson (1984). After blocking with 1% bovine serum albumin in
phosphate-buffered saline, blots were incubated for 1 h with a biotin-
conjugated C-terminal and a N-terminal monoclonal antibody against
MIA (Boehringer Mannheim) in two different reactions to detect MIA
and MIA(splice) separately. Washing the blots was followed by
incubation with a second streptavidin±peroxidase conjugated antibody.
For color development, diaminobenzoid was used as a substrate.
Anti-serum against MIA(splice) A synthetic peptide, resembling the
putative amino acid sequence of MIA(splice), was synthesized (QCB, #3
Avenue D, Hopkinton, MA 01748), puri®ed, and used as an antigen to
immunize rabbits. The synthetic peptide contains all 36 amino acids of
the original endogenous peptide MIA(splice). Serum of the rabbits
was af®nity puri®ed and tested for speci®city (not shown).
Figure 1. Expression of MIA(splice) in a northern blot analysis.
The bands show MIA (runs at 539 bases), MIA(splice) (runs 134 bases
lower at 405 bases), and b-actin (used as a control). In the lanes, two cell
lines of cerebral metastases of human malignant melanoma, HTZ-19 and
CRL-1424 (ATCC), and FV, a human ®broblast cell line, are shown.
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Immunohistochemistry was done in a 1 : 200±500 dilution of the serum
as described below.
Immunohistochemistry For immunohistochemistry, standard 5 mm
sections of formalin-®xed and paraf®n-embedded tissues were used.
Immunohistochemical staining was performed using an indirect
immunoperoxidase protocol according to the LSAB2 kit (Dako,
Hamburg, Germany). Sections were incubated with the following
antibody dilution: mouse monoclonal anti-MIA, 1 : 40, and rabbit
polyclonal anti-MIA(splice), 1 : 200±500. Characterization of the 2F7
anti-MIA antibody included immunoprecipitation of MIA protein from
tissue culture supernatant visualizing a single 11 kDa signal speci®cally
for melanoma cells.
RESULTS
Detection, molecular cloning, and sequencing of
MIA(splice) Using northern blot to analyze MIA expression
pattern, we detected a second signal when using complete MIA
cDNA as a probe. As the known MIA mRNA runs at 539 bases,
the new signal ran at approximately 405 bases (Fig 1).
Several approaches were used to assess the biologic relevance of
the signal and to analyze the peptide. The band for the putative
MIA(splice) was cut out of the agarose gel, using the autoradiogram
as a template, and cloned into the vector pCR-Script Cam SK(+)
(Stratagene, 11011 N. Torrey Pines Road, La Jolla, CA 92037)
by reverse transcriptase±PCR ampli®cation of eluted RNA.
Subsequent sequencing revealed a size reduction in the mRNA
of 134 bp, indicating an alternative splice product of the MIA gene.
Owing to alternative splicing, exon 2 is missing and, in addition,
splicing causes a frameshift in the open reading frame, resulting in a
distinct and unique C-terminal portion of the protein. The loss of
exon 2 combined with the frameshift results in a protein consisting
of 36 amino acids with a molecular weight of 3.5 kDa. This
theoretical weight could be veri®ed by recombinant expression of a
fusion protein (with dihydrofolate reductase) and by western blot
analysis of supernatants from cell cultures (Fig 2), showing
immunoreactivity to the originally described full length MIA,
running at 11 kDa, when using a N-terminal speci®c antibody, as
Table I. Expression pattern list of MIA and MIA(splice) in
melanoma and control tissue samples or cell cultures as
detected by reverse transcriptase±PCR. Tumors are graded
according to the pTNM system. Expression of MIA(splice) is
strongly correlated to the expression of MIA in all primary
cultures tested so far. The ratio of the PCR products of MIA to
MIA(splice) in melanocytic cells is almost constant in all primary
cultures tested, whereas in nonmelanocytic MIA-positive controls,
the expression of MIA(splice) is relatively low compared
with MIA.
mRNA expression
MIA(splice)
mRNA expression
MIA
Melanocytic tumors
Nevus
A1 ± +++
A2 ++++ +++++
A3 ++++ ++++
A4 ++ +++++
A5 ++++ ++++
A6 +++ +++++
Melanoma (pTx Nx M0)
B1 ++ ++++
B2 ++ +++
B3 ++ +++
B4 +++ ++
B5 ± +
B5 ++ +++
Primary site of metastatic melanoma (pTx Nx M1b)
C1 ± +
C2 ++++ ++++
C3 +++++ +++
C4 + +
C5 ++ ++
C6 +++ ++
C7 + ++
C8 ++ ++
C9 ++ ++
C10 ++ ++
C11 ++ ++
C12 + ++
Systemic metastases of melanoma (pTx Nx M1b)
D1 + ++++
D2 + +++
D3 +++ ++++
D4 +++++ +++
D5 ++++ +++
D6 ++++ +++++
D7 ++ ++++
D8 ++ ++++
D9 + ++++
D10 +++ ++
CNS metastases of melanoma (pTx Nx M1b)
E1 + +
E2 + ++
E3 + +
E4 ++ +
Primary cultures of melanoma
F1 +++ ++++
F2 ++++ +++
F3 ++++ +++
F4 +++ ++++
F5 ++++ +++
F6 ± +
F7 ++++ +++
F8 ± ++
Nonmelanocytic tumors
G1 ++ +++
G2 ± +++
G3 + +++
G4 + ++
G5 + +++
G6 + +++
G7 + +++
G8 + ++
pTx Nx M0, no distant metastasis; pTx Nx M1b, visceral distant metastasis; A,
melanocytic nevi; B, melanomas; C, primary sites of metastatic melanomas; D,
systemic metastasis of melanomas; E, CNS metastasis of melanomas; F, primary
cultures of melanomas; G, controls consisting of nonmelanocytic tumors: G1±4,
basalioma; G5, endothelium; G6, healthy colon; G7, colitis; and G8, carcinoma of
the colon.
Figure 2. Western blot analysis of supernatants from cell cultures,
showing immunoreactivity to the originally described full length
MIA, using a N-terminal speci®c antibody, as well as to a protein
band migrating at the predicted molecular weight of the splice
form of about 3.5 kDa. Staining of this lower band is not detectable
when using a C-terminal-speci®c antibody against MIA. In the bands,
MIA and MIA(splice) are displayed. In the lanes, a marker, which was
enhanced in this ®gure, and the reaction with a N-terminal antibody in
the left panel and a C-terminal antibody in the right panel are shown. In
each panel, the lanes show 1 melanoma cell line obtained from ATCC
(CRL-1424), two cell lines of cerebral metastasis of human malignant
melanoma and two cell lines of human malignant glioma (HTZ-cell
lines, established in our laboratory).
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well as to a second protein band migrating at the predicted
molecular weight of the spliced form of about 3.5 kDa. This lower
band, however, was not detectable when using a C-terminal
speci®c antibody against MIA.
An extensive database search showed no homology to known
sequences. The consensus sequences for the splicing donor and
acceptor sites are preserved. All splicing sites start with GT at the
5¢-end and end with AG at the 3¢-end of the exons (Breathnach et
al, 1978). Exon 1 contains the secretion signal (72 bp coding for 24
amino acids) and the codons for the ®rst 18 amino acids of the
mature peptide as described for MIA. After complete excision of
exon 2, a frameshift occurs, causing a different amino-acid
sequence in the C-terminal part of the peptide. After another 18
amino acids of exon 3, a stop codon (TAG) interrupts the sequence
of the spliced peptide (Figs 3 and 4).
Three of the four cysteine residues of MIA are preserved,
allowing intramolecular and intermolecular disul®de bonds. As
MIA(splice) could be detected by an N-terminal speci®c antibody,
three-dimensional con®rmation seems to be preserved.
Expression pattern of MIA(splice) Cell lines of melanocytic
origin and of gliomas and tissue of melanocytic and other origin
were screened for expression of the full length protein and the
alternative spliced form. MIA(splice) is coexpressed with MIA in
almost all tissues and cell lines tested. Expression was shown in
tissue of ®ve of six primary melanomas (stage pTx Nx M0), 11 of
Figure 3. Using a PCR approach, sequencing of MIA(splice) was performed revealing a sequence identical to that of MIA, however,
lacking 134 bp of exon 2 of the original sequence and thus resulting in a frameshift. Regular typed amino acids indicate the identical sequence
of the proteins MIA and MIA(splice). Italic typed amino acids indicate the unique sequence of MIA and regular and lighter typed amino acids indicate
the unique C-terminal protein sequence of MIA(splice).
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12 primary sites of metastatic melanomas (stage pTx Nx M1b), 10
of 10 systemic metastasis of melanoma (stage pTx Nx M1b), four of
four CNS metastases of melanoma (stage pTx Nx M1b), and six of
eight primary melanoma cell cultures. Only a faint signal was
obtained in tissue samples of ®ve of six naevi. Interestingly, seven of
eight controls representing nonmelanocytic tissue positive for MIA
(basalioma, endothelium, healthy colon, colitis, and carcinoma of
the colon) showed weak expression of MIA(splice) (Fig 5,
Table I).
The ratio of the PCR products of MIA and MIA(splice) in
melanocytic cells is almost constant in all tissues and cultures tested,
whereas in nonmelanocytic MIA-positive tissues or cultures, the
expression of MIA(splice) is relatively low compared with the
nonspliced cDNA (Tables I and II).
In addition, ®ve of seven malignant glioma cell cultures tested
were found positive as well (Table II). Translation of MIA and
MIA(splice) mRNA to protein was con®rmed in a selected number
of cell lines by western blot analysis. Protein expression was
con®rmed in three of three cell lines of malignant melanomas and
in two of two glioma cell lines as speci®ed above and correlated
strongly to the expression of mRNA (Fig 2).
Tissue distribution In contrast to the localization of MIA,
which is a secreted protein and consequently is detected mainly in
the cytoplasm of MIA-positive cells, MIA(splice) shows a more
nuclear localization (Fig 6).
The scattered appearance within a given cell culture or tissue
specimen, respectively, leads to the speculation that the expression
Figure 4. The genomic DNA consists of four exons and two noncoding introns. Exon 1 consists of the bases for the ®rst 18 amino acids of
the peptide as described for MIA above. After complete lack of exon 2, a frameshift causes a different amino-acid sequence in the second part of the
peptide. An additional Histidine residue (amino acid 43) is generated by regular splicing of exon 1 to exon 2 and is not indicated here.
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of MIA(splice) may be associated with the regulation of the cell
cycle. Interestingly, in a series of stainings of cutaneous nevi,
melanoma in situ, and melanoma metastasis, there is a clear relation
of the expression of MIA(splice) to the stage of tumorigenesis
(Fig 7).
Regulation of MIA and MIA(splice) MIA and MIA(splice) are
inversely regulated if incubation TGF-b2 is performed in cell
culture (Fig 8). The mRNA of MIA is, antagonistic to TGF-b2,
almost completely downregulated after 3 h of incubation, whereas
the signal for MIA(splice) is, agonistic to TGF-b2, upregulated.
Both signals are back to untreated levels 48 h after incubation.
DISCUSSION
MIA is mainly expressed in cartilage during embryogenesis, and, in
adulthood, is related to invasion, metastasis, and immunomodula-
tion of melanoma and glioma cells in vivo and in vitro (Jachimczak et
al, manuscript in preparation). Here, we describe an alternative
splice product termed MIA(splice), lacking exon 2 of the original
protein. A predicted frameshift results in a unique C-terminal
portion of the protein. A protein migrating at the predicted
molecular weight of the splice form (3.5 kDa) was detected using a
N-terminal speci®c antibody. Expression was shown in most
primary melanomas, primary sites of metastatic melanomas,
systemic metastasis of melanoma, CNS metastases of melanomas,
primary melanoma cultures, and malignant melanoma cell lines.
Only a faint signal was obtained in tissue samples of naevi.
Interestingly, some nonmelanocytic cell lines and glioma cell lines
showed weak expression of MIA(splice) as well. An extensive
search in commonly used databases showed that MIA(splice) has no
homology to any other protein known so far.
Alternative splicing is a widely used mechanism involved in
physiologic regulatory processes. In most cases, alternative splicing
leads to functional proteins as in the case of the NK-TR-gene
(``natural killer-cell tumor-recognition protein''; Rinfret and
Anderson, 1993). During activation of natural killer cells by
interleukin-2, a change in the splicing pattern with enhanced
production of unspliced mRNA is induced. Consecutively, the full
length form of the protein is translated, and an enhanced response
of the natural killer cells against tumor cells is possible. In contrast,
alternative splicing can also lead to insuf®cient gene products and
therefore can be correlated with pathologic conditions. Alternative
splicing of the MEN1 tumor suppressor gene, for example, leads to
an enhanced range of multiple endocrine neoplasias (Mutch et al,
1999). Splicing of the transcription factor PAX-2 leads to the
development of inborn colobomas (Tavassoli et al, 1997), mutation
of the receptor for interferon-a to the development of myeloma
(Abramovich et al, 1994). The splicing of the NF-2-gene leads to
Table II. Expression pattern list for mRNA and protein of MIA and MIA(splice) in tissue samples and cell lines of
melanomas, low- and high-grade gliomas and other nonmelanocytic tissue as speci®ed in Table I. Melanoma cell lines are
CRL-1424 and HTB-69 from ATCC, cell lines from CNS-metastases of melanomas are HTZ cell lines established in our laboratory.
Glioma cell lines were in part from ATCC as speci®ed in Materials and Methods, and in part established in our laboratory. mRNA was
tested by reverse transcriptase±PCR and con®rmed by northern blot in some cases. Western blot was not done (ND) from tissue samples
due to lack of material and was performed in a representative selection of MIA and MIA(splice)-positive cell lines of malignant
melanomas and of high-grade gliomas. MIA(splice) is expressed in a wide variety of tumors and expression is correlated to MIA as shown
in Table I. Numbers indicate cell lines positive in comparison with cell lines tested (n/n)
MIA(splice)
mRNA
MIA mRNA
mRNA
MIA(splice)
protein
MIA
protein
Melanoma
Melanocytic nevus tissue 5/6 6/6 ND ND
Melanoma tissue 5/6 6/6 ND ND
Primary site of metastatic melanoma tissue 11/12 12/12 ND ND
Systemic metastasis of melanoma tissue 10/10 10/10 ND ND
CNS metastasis of melanoma tissue 4/4 4/4 ND ND
Melanoma primary cultures 6/8 8/8 ND ND
Melanoma cell lines 2/2 2/2 2/2 2/2
CNS metastasis of melanoma cell lines 3/3 3/3 3/3 3/3
Malignant glioma
Low-grade (WHO I/II) cell lines 1/3 1/3 ND ND
High-grade (WHO III/IV) cell lines 6/6 4/4 2/2
Nonmelanocytic tumors
Tissue 7/8 8/8 ND ND
Figure 5. Reverse transcriptase±PCR from tissue of six naevi, six
melanomas, 12 primary sites of metastatic melanomas, 10
systemic metastasis of melanomas, four CNS metastasis of
melanomas, eight primary melanoma cultures, and eight controls
(basalioma, n = 4; endothelium, n = 1; healthy colon, n = 1;
colitis, n = 1; and carcinoma of the colon, n = 1). In the lanes,
MIA(splice), MIA, and GAPDH (control) are shown for each specimen;
marker 8 (Roche Pharma, Roche Diagnostics AG, Industriestrasse 7,
6343 Rotkreuz, Switzerland) was used as a weight marker. Expression
levels of melanocytic tumors correlate with the malignancy of tumors.
MIA(splice) can be detected in nonmelanocytic controls as well, but to a
much weaker extent.
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the development of multiple schwannomas (Jacoby et al, 1994).
Alternative splicing of the PTEN gene, which is important in a
broad range of human primary brain tumors, is detected in about
20% of Burkitt's lymphomas and in about 3% of all non-Hodgkin
lymphoma (Butler et al, 1999). Splicing of the BRCA1 gene with
consecutive translation of a protein incapable of performing the
hypothesized tumor suppressor function, was described in a family
with cases of breast cancer (Hoffman et al, 1998).
Relating to that, elucidation of ®rst functional aspects was a
major concern after detection of MIA(splice). MIA(splice) can be
detected with an N-terminal antibody, which is evidence for a
three-dimensional con®guration of the peptide and makes a
functional role in vivo likely. MIA(splice) is frequently expressed
in neuroectodermal tissue samples and cell cultures of different
histologic origin, mainly in malignant melanoma and glioma.
Expression of MIA(splice) is strongly correlated with the expression
of MIA in all tumors tested so far. Interestingly, the ratio of the
PCR products of MIA to MIA(splice) in melanocytic cells is
almost constant in all specimens tested, whereas in
nonmelanocytic MIA-positive specimens, the expression of
MIA(splice) is relatively low compared with the nonspliced
cDNA. The observation that an alternative splice product is
coexpressed in all melanocytic cells tested here, but shows a
signi®cantly lower degree of expression in nonmelanocytic cells,
may suggest that this new peptide is especially involved in the
development of melanocytic tumors; this may de®ne a role for
MIA(splice) in the discrimination of different tumors with
methods, such as enzyme-linked immunosorbent assay for MIA
and MIA(splice) and eventually for therapeutic targeting of
tumors expressing signi®cant amounts of MIA(splice). In addition,
MIA(splice) shows a more nuclear localization, whereas MIA,
which is a secreted protein, is preferentially located in the
cytoplasm, which leads to the speculation that MIA(splice) may
be associated with the regulation of the cell cycle. Furthermore, as
in MIA, there is a clear relation of the expression of MIA(splice) to
the stage of tumorigenesis, which may indicate a role as a marker
of progression. Finally, MIA and MIA(splice) are inversely
regulated after incubation with TGF-b2. The mRNA of MIA is
regulated in an antagonistic way in comparison with TGF-b2,
whereas the signal for MIA(splice) is, agonistic to TGF-b2,
upregulated. As TGF-b2 and MIA are known to be involved in
the regulation of, for example, tumor invasion in malignant
Figure 6. PAP stain of different tumors and ®broblasts treated
with serum of a rabbit immunized against MIA(splice) (A1, ®rst
row, left) and MIA (B1, C1, D1, E1, F1, next rows, left), and
controls (A2, B2, C2, D2, E2, F2, right). (A,B) HTZ-19, malignant
melanoma; (C) HTZ-318, malignant melanoma; (D) HTZ-17,
glioblastoma; E: HTZ-146, glioblastoma; and (F) H-36, embryonal
®broblasts. With the antibody generated against MIA(splice), a more
nuclear staining pattern is detected in comparison with the antibody
against MIA, where a more cytoplasmatic staining pattern was detected.
Figure 7. PAP stain of different stages of melanocytic tumors
treated with the serum of a rabbit immunized against
MIA(splice). (A) Naevus; (B) primary site of malignant melanoma; (C)
metastasis of malignant melanoma. A very faint nuclear staining pattern is
detected in the nevus, whereas in the primary site melanoma, staining is
enhanced. In the metastasis, the most prominent nuclear staining pattern
was detected.
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melanoma, MIA(splice) may have a different function, for example
as an antagonist to MIA or as a transcription factor expressed if MIA
is upregulated.
Taken together, MIA(splice) appears to be an important protein
with a distinct function in comparison with MIA. It may play a
major part in the development of malignant melanoma and glioma
and could be a useful tool for the differential diagnosis of different
stages of these tumors.
F5- and H-36 ®broblasts were kindly provided by the 1nstitute of Pathology,
University of Regensburg, Germany.
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